Deferred Tax Assets, Valuation Allowance of Enliven Therapeutics, Inc. from 31 Dec 2019 to 31 Dec 2025

Taxonomy & unit: us-gaap: USD
Description: Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary: Enliven Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2019 to 31 Dec 2025.
Enliven Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $92,278,000, a 45% increase year-over-year.
Source SEC data: View on sec.gov

Deferred Tax Assets, Valuation Allowance, Quarterly (USD)

Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Enliven Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q4 2025	$92,278,000	+$28,566,000	+45%	31 Dec 2025	10-K	03 Mar 2026	2025	FY
Q4 2024	$63,712,000	+$20,926,000	+49%	31 Dec 2024	10-K	03 Mar 2026	2025	FY
Q4 2023	$42,786,000	+$23,235,000	+119%	31 Dec 2023	10-K	13 Mar 2025	2024	FY
Q4 2022	$19,551,000	+$10,073,000	+106%	31 Dec 2022	10-K	14 Mar 2024	2023	FY
Q4 2021	$9,478,000	-$20,671,000	-69%	31 Dec 2021	8-K	23 Jun 2023
Q4 2020	$30,149,000	+$14,764,000	+96%	31 Dec 2020	10-K	15 Mar 2022	2021	FY
Q4 2019	$15,385,000			31 Dec 2019	10-K	05 Mar 2021	2020	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.